ACIU - AC Immune SA
2.7
-0.190 -7.037%
Share volume: 260,545
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.18%
PREVIOUS CLOSE
CHG
CHG%
$2.89
-0.19
-0.07%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-6.25%
1 Month
-6.25%
3 Months
-16.92%
6 Months
-22.19%
1 Year
-22.19%
2 Year
-22.19%
Key data
Stock price
$2.70
DAY RANGE
$2.70 - $2.92
52 WEEK RANGE
$2.44 - $4.00
52 WEEK CHANGE
-$22.19
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Andrea Pfeifer
Region: US
Website: acimmune.com
Employees: 140
IPO year: 2016
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: acimmune.com
Employees: 140
IPO year: 2016
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.
Recent news